
Energy, Mobility
FLAGSHIP
The FLAGSHIP project aims to demonstrate the cost-effectiveness of a 10MW floating offshore wind turbine (TEMF) to ensure LCOE reduction...
RBD Dimer recombinant protein vaccine against SARSCoV2
Project dates
2021 - 2024
Website
Role of Zabala
Partner
Project led by
HIPRA SCIENTIFIC SL (HIPRA SCIENTIF)
13
Partners
5
Countries
9
M€ budget
30
Months
Since the publication of the genome sequence of SARS-CoV2, on January 11th, 2020, an endeavour of unprecedented speed and magnitude set out to develop a vaccine against the disease. An ideal SARS-CoV-2 vaccine should meet the following requirements: protect not only from severe disease but also thwart infection in all vaccinated populations, including less immunocompromised individuals, elicit long term memory immune responses after a minimal number of immunizations or booster doses, able to ramp up production to produce billions of doses.
RBDCOV will provide a vaccine that should meet the following requirements: protect not only from severe disease but also thwart infection in all vaccinated populations, including less immunocompromised individuals; elicit long term memory immune responses after a minimal number of immunizations of booster doses; able to ramp up production to produce billions of doses annually and be easily accessible for worldwide vaccination campaigns at an affordable cost and at limited time.
RBDCOV is an ambitious project that will offer a new tool to control the pandemic in the short-medium and long term. RBDCOV aims to manufacture and test the first recombinant protein-based vaccine to be licensed in Europe beyond the scope of the project. The final formulation of RBDCOV vaccine, the company’s experience in the use of highly innovative platforms for the manufacture of vaccines animal vaccine manufacturing and the strong consortium involved in the RBDCOV project will make it feasible to lay the foundation for this challenging goal.
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.
“RBDCOV mission was generated, trying to obtain a safe and efficient vaccine against COVID in a short term by merging for the first time the knowledge and capacities of key actors internationally renowned from the field of animal and human vaccine research and development. ”
Laura Sesma
Health Area Leader
Energy, Mobility
The FLAGSHIP project aims to demonstrate the cost-effectiveness of a 10MW floating offshore wind turbine (TEMF) to ensure LCOE reduction...
Energy, Mobility
The goal of the new ETIP HYDROPOWER is to enhance the cooperation among diverse stakeholders in the hydropower industry to...
Climate, Natural Resources and Environment
Waste4Think promotes a major transformation of the current waste management model to meet the foundations on which the principles of...
News
OPEN CALL
Opinion
SECURITY R&D PROJECTS
Jorge Lorente
R&I Consultant
Publication
KAILA
In Kaila, our smart platform, we have developed a definitive Horizon Europe calendar, the only one that includes all the call dates of the new Framework Programme. Download it now!
The important thing is not to keep moving, but rather to know in which direction to go. Our 37% success rate proves that we know how to guide our clients.
Our compass is our clients; our mission is to solve their problems, guiding them so that innovation becomes their key to competitiveness.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.